Prodrugs of a 1-Hydroxy-2-oxopiperidin-3-yl Phosphonate Enolase Inhibitor for the Treatment of <i>ENO1</i>-Deleted Cancers-Reference-Cited by-同舟云学术

Prodrugs of a 1-Hydroxy-2-oxopiperidin-3-yl Phosphonate Enolase Inhibitor for the Treatment of ENO1-Deleted Cancers

Published:2022-10-17 Issue:20 Volume:65 Page:13813-13832
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Yan Victoria C.¹^ORCID,Pham Cong-Dat¹,Ballato Elliot S.¹,Yang Kristine L.¹,Arthur Kenisha¹,Khadka Sunada¹²,Barekatain Yasaman¹²^ORCID,Shrestha Prakriti¹,Tran Theresa¹,Poral Anton H.¹,Washington Mykia¹,Raghavan Sudhir¹,Czako Barbara³,Pisaneschi Federica¹,Lin Yu-Hsi¹^ORCID,Satani Nikunj¹^ORCID,Hammoudi Naima¹,Ackroyd Jeffrey J.¹,Georgiou Dimitra K.¹,Millward Steven W.¹^ORCID,Muller Florian L.¹^ORCID

Affiliation:

1. Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas 77054, United States

2. Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, Texas 77054, United States

3. Institute of Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, Texas 77054, United States

Funder

National Cancer Institute

Andrew Sabin Family Foundation

Uncle Kory Foundation

National Comprehensive Cancer Network

American Cancer Society

University of Texas MD Anderson Cancer Center

Dr. Marnie Rose Foundation